Oncotarget

Research Papers:

Integrated analysis of long non-coding RNAs in human colorectal cancer

Xiaohua Chen, Binjian Liu, Rui Yang, Yong Guo, Feng Li, Lin Wang and Hanyang Hu _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:23897-23908. https://doi.org/10.18632/oncotarget.8192

Metrics: PDF 1040 views  |   HTML 1595 views  |   ?  


Abstract

Xiaohua Chen1,2, Binjian Liu2, Rui Yang3, Yong Guo4, Feng Li1, Lin Wang1, Hanyang Hu1

1School of Basic Medical Sciences, Wuhan University, Wuhan, China

2Department of Laboratory Medicine, No.161 Hospital of PLA, Wuhan, China

3Department of General Surgery, No.161 Hospital of PLA, Wuhan, China

4Department of Pathology, No.161 Hospital of PLA, Wuhan, China

Correspondence to:

Hanyang Hu, e-mail: huhanyang923@163.com

Keywords: lncRNA, colorectal cancer, expression profiling, epigenetic regulation, poor-prognosis

Received: August 27, 2015     Accepted: February 28, 2016     Published: March 19, 2016

ABSTRACT

Accumulating evidence highlights the role of long non-coding RNAs (lncRNAs) in tumors. However, the genome-wide expression and roles of lncRNAs in colorectal cancer (CRC) remain unknown. Here, we systematically examined the global gene expressions in primary and synchronous liver metastases CRC tissue, in which thousands of aberrantly expressed lncRNAs were characterized. Co-expression analysis revealed that some lncRNAs correlated to their neighboring mRNAs in expression levels, whereas others formed networks with protein-coding genes in trans. We observed H3K4me3 was enriched at expressed lncRNA transcription start sites (TSSs) and correlated to dysregulated lncRNAs. Furthermore, we identified primary and metastasis tumor linked lncRNA signatures positively correlated with poor-prognosis gene set. Finally, functional experiments demonstrated two candidate lncRNAs were required for proliferation and migration of CRC cells. In summary, we provided a new framework for lncRNA associated clinical prognosis evaluation and target selection of gene therapy in CRC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8192